St Vincent's Hospital Clinical School, University of New South Wales, Kensington, New South Wales, Australia.
J Heart Lung Transplant. 2011 Jul;30(7):783-9. doi: 10.1016/j.healun.2011.01.728. Epub 2011 Apr 9.
Owing to persisting donor shortages, the use of "marginal hearts" has increased. Because patients who receive a marginal heart may require hemodynamic support in the early post-operative period, extracorporeal membrane oxygenation (ECMO) may be used until recovery of acute graft dysfunction.
A retrospective file review of 124 primary adult heart transplant patients from 2003 to 2008 was conducted. We compared 17 patients who received post-transplant ECMO support with 107 transplant recipients without ECMO. Donor and recipient pre-transplant, intra-operative, and post-transplant clinical variables to 6 months after transplant were compared.
Pre-operative demographics of the 2 groups were similar. Eight (47%) of the patients in the ECMO group received marginal donor hearts, compared with 1 (1%) in the non-ECMO group (p < 0.05). There were 3 early deaths in the ECMO group (2 of whom had received optimal donor hearts), resulting in lower Day 30 ECMO survival of 82.4% vs 100% for non-ECMO, respectively (p < 0.001), and 6-month survival of 82.4% vs 95.6%, respectively (p < 0.02). Most of the difference in survival was in patients who required salvage ECMO despite normal pre-transplant donor LV function. The rate of early dialysis was higher in the ECMO group, at 18% vs 6% at Day 3, but there was no difference between the 2 groups by Day 7. Pre-discharge ventricular function was normal in all discharged ECMO patients and all but 1 non-ECMO patient. ECMO patients had a longer intensive care unit stay (8.9 ± 3.4 vs 4.8 ± 5.4 days, p < 0.005), but there was a slightly shorter ward stay, resulting in a similar overall hospitalization length of stay (22.9 ± 8.3 vs 25.1 ± 25.2 days).
ECMO allows for salvage of acute graft dysfunction and may allow use of marginal donor hearts. Survival rates are lower in patients who require ECMO compared with optimal donors, but early cardiac dysfunction normalizes in most without long-term cardiac or renal sequelae. Despite longer ventilation times, overall hospitalization is not prolonged.
由于持续的供体短缺,“边缘心脏”的使用有所增加。由于接受边缘心脏的患者在术后早期可能需要血流动力学支持,因此可能会使用体外膜肺氧合(ECMO)直到急性移植物功能障碍恢复。
对 2003 年至 2008 年 124 例成人心脏移植患者的回顾性文件进行了回顾。我们比较了 17 例接受移植后 ECMO 支持的患者和 107 例未接受 ECMO 的移植受者。比较了两组患者移植前、移植术中及移植后 6 个月的临床变量。
两组患者的术前人口统计学特征相似。ECMO 组中有 8 例(47%)患者接受了边缘供体心脏,而非 ECMO 组有 1 例(1%)(p<0.05)。ECMO 组有 3 例早期死亡(其中 2 例接受了最佳供体心脏),因此 ECMO 组第 30 天的 ECMO 存活率分别为 82.4%和 100%(p<0.001),6 个月的存活率分别为 82.4%和 95.6%(p<0.02)。存活率的差异主要在于尽管术前供体左心室功能正常,但仍需要挽救性 ECMO 的患者。ECMO 组的早期透析率较高,第 3 天为 18%,而非 ECMO 组为 6%,但第 7 天两组之间无差异。所有出院的 ECMO 患者和除 1 例非 ECMO 患者外,所有出院患者的出院前心室功能均正常。ECMO 患者的重症监护病房停留时间较长(8.9±3.4 天 vs. 4.8±5.4 天,p<0.005),但住院时间略短,因此总住院时间相似(22.9±8.3 天 vs. 25.1±25.2 天)。
ECMO 可挽救急性移植物功能障碍,并可使用边缘供体心脏。与最佳供体相比,需要 ECMO 的患者的存活率较低,但大多数患者的早期心功能障碍会恢复正常,没有长期的心脏或肾脏后遗症。尽管通气时间较长,但总住院时间并未延长。